中文摘要
卵巢癌仍然是最致命的妇科恶性肿瘤,然而免疫检查点抑制剂(ICIs)由于高度异质性肿瘤免疫微环境(TME)中CD8+ T细胞深度耗竭而表现出有限的临床疗效。单细胞RNA测序(scRNA-seq)通过解析稀有免疫亚群、重建谱系轨迹和绘制动态细胞间信号网络,彻底改变了我们对这一复杂生态系统的理解。新兴的单细胞图谱揭示,终末耗竭T细胞由可塑性祖细胞群体演化而来,尤其是GZMK+亚群,而腹水作为一种独特的免疫调节储库,持续塑造瘤内免疫动态。
此外,多区室转录组分析揭示了髓系-淋系串扰 actively 维持局部免疫抑制并驱动治疗耐药。这些高分辨率分子见解正日益被用于准确预测ICI应答、合理设计新型联合方案以及策略性指导下一代过继性细胞疗法。本综述总结了scRNA-seq驱动的卵巢癌TME表征进展,强调单细胞分辨率如何 dismantle 免疫抑制屏障以促进T细胞再激活,并为精准免疫治疗建立稳健的转化框架。
展开英文摘要原文
Ovarian cancer remains the most lethal gynecological malignancy, yet immune checkpoint inhibitors (ICIs) demonstrate limited clinical efficacy due to profound CD8 +- T cell exhaustion within a highly heterogeneous tumor immune microenvironment (TME). Single-cell RNA sequencing (scRNA-seq) has revolutionized our understanding of this complex ecosystem by resolving rare immune subsets, reconstructing lineage trajectories, and mapping dynamic intercellular signaling networks.
Emerging single-cell atlases reveal that terminally exhausted T cells evolve from plastic progenitor populations, notably GZMK +- subsets, while ascitic fluid functions as a distinct immunomodulatory reservoir that continuously shapes intratumoral immune dynamics.
Furthermore, multi-compartment transcriptomic profiling uncovers myeloid-lymphoid crosstalk that actively sustains localized immunosuppression and drives therapeutic resistance. These high-resolution molecular insights are increasingly leveraged to accurately predict ICI responsiveness, rationally design novel combinatorial regimens, and strategically guide next-generation adoptive cellular therapies.
This review summarizes the scRNA-seq-driven advances in characterizing the ovarian cancer TME, emphasizing how single-cell resolution dismantles immunosuppressive barriers to T cell reinvigoration and establishes a robust translational framework for precision immunotherapy.
论文信息
- 作者
- Shen M、Zhang S、Zhu Y、He Q、Chen W
- 第一作者单位
- Department of Obstetrics and Gynecology, Hangzhou Xiaoshan Second People's Hospital, Hangzhou, China.China
- 通讯作者单位
- Quality Management Department, Hangzhou Xiaoshan Second People's Hospital, Hangzhou, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2026